This 2nd position paper of our 2023 Medical Series proposes 5 recommendations and several tools to develop High-Performance Strategic Medical Plans.
News
Developing a strategy for rare diseases in France requires a clear understanding of the care ecosystem, key...
The French Voluntary Trade Organization (VTO) market is consolidating, making VTOs increasingly important partners for pharma companies...
« High-performance Market Access Brand Plans require method, rigor and pragmatism » Our new publication on how to build...